- Home
- ALLO vs CYH Comparison
ALLO vs CYH Comparison
Compare ALLO & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- CYH
- Stock Information
- Founded
- ALLO 2017
- CYH 1985
- Country
- ALLO United States
- CYH United States
- Employees
- ALLO N/A
- CYH N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- CYH Hospital/Nursing Management
- Sector
- ALLO Health Care
- CYH Health Care
- Exchange
- ALLO Nasdaq
- CYH Nasdaq
- Market Cap
- ALLO 677.5M
- CYH 623.8M
- IPO Year
- ALLO 2018
- CYH 1991
- Fundamental
- Price
- ALLO $2.27
- CYH $3.85
- Analyst Decision
- ALLO Buy
- CYH Hold
- Analyst Count
- ALLO 12
- CYH 5
- Target Price
- ALLO $10.06
- CYH $5.20
- AVG Volume (30 Days)
- ALLO 2.6M
- CYH 2.5M
- Earning Date
- ALLO 11-07-2024
- CYH 10-23-2024
- Dividend Yield
- ALLO N/A
- CYH N/A
- EPS Growth
- ALLO N/A
- CYH N/A
- EPS
- ALLO N/A
- CYH N/A
- Revenue
- ALLO $43,000.00
- CYH $12,551,000,000.00
- Revenue This Year
- ALLO N/A
- CYH $1.19
- Revenue Next Year
- ALLO $5,902.96
- CYH $1.48
- P/E Ratio
- ALLO N/A
- CYH N/A
- Revenue Growth
- ALLO 26.47
- CYH 0.81
- 52 Week Low
- ALLO $2.01
- CYH $2.31
- 52 Week High
- ALLO $5.78
- CYH $6.29
- Technical
- Relative Strength Index (RSI)
- ALLO 36.00
- CYH 30.86
- Support Level
- ALLO $2.95
- CYH $4.08
- Resistance Level
- ALLO $3.36
- CYH $4.64
- Average True Range (ATR)
- ALLO 0.26
- CYH 0.26
- MACD
- ALLO -0.06
- CYH -0.02
- Stochastic Oscillator
- ALLO 0.91
- CYH 7.02
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.